Abstract
Protection to sexually transmitted infections with oncogenic human papillomaviruses (HPV) such as type 16 is thought to be provided by neutralizing antibodies directed to the major outer capsid protein, the L1 protein. A DNA vaccine and an E1-deleted adenoviral recombinant human strain 5, both expressing the L1 protein of HPV-16, were developed and shown to express L1 protein able to assemble into virus-like particles (VLPs). The vaccines used in a prime-boost regimen, with the DNA given intramuscularly (i.m.) for priming, followed by an intranasal (i.n.) booster immunization with the viral recombinant, induced antibodies to L1 in sera and in vaginal secretions.
Publication types
-
Research Support, Non-U.S. Gov't
-
Research Support, U.S. Gov't, P.H.S.
MeSH terms
-
Administration, Intranasal
-
Animals
-
Antibodies, Viral / biosynthesis
-
Antigens, Viral / chemistry
-
Antigens, Viral / genetics
-
COS Cells
-
Capsid Proteins*
-
Cell Line
-
Epitopes / chemistry
-
Epitopes / genetics
-
Female
-
Humans
-
Immunization, Secondary
-
Injections, Intramuscular
-
Mice
-
Mice, Inbred C57BL
-
Microscopy, Electron
-
Oncogene Proteins, Viral / genetics
-
Oncogene Proteins, Viral / immunology
-
Papillomaviridae / genetics
-
Papillomaviridae / immunology*
-
Papillomaviridae / pathogenicity
-
Papillomaviridae / ultrastructure
-
Papillomavirus Infections / immunology*
-
Papillomavirus Infections / prevention & control*
-
Papillomavirus Vaccines
-
Tumor Virus Infections / immunology*
-
Tumor Virus Infections / prevention & control*
-
Vaccines, DNA / administration & dosage
-
Vaccines, DNA / genetics
-
Vaccines, Synthetic / administration & dosage
-
Vaccines, Synthetic / genetics
-
Viral Vaccines / administration & dosage
-
Viral Vaccines / genetics
Substances
-
Antibodies, Viral
-
Antigens, Viral
-
Capsid Proteins
-
Epitopes
-
Oncogene Proteins, Viral
-
Papillomavirus Vaccines
-
Vaccines, DNA
-
Vaccines, Synthetic
-
Viral Vaccines
-
L1 protein, Human papillomavirus type 16